Salute e Benessere
Global Alzheimer's Disease Therapeutics and Diagnostics Market to Grow at 15.1% CAGR
This in-depth analysis provides a comprehensive overview of the global market for AD diagnostics and therapeutics. It focuses on biomarker tests for AD while excluding cognitive tests and neuroimaging methods. The diagnostics market is segmented by test type and region. In the therapeutics segment, the report covers only pharmacological treatments, excluding alternative treatments and off-label drugs used for managing non-cognitive symptoms like agitation and depression. The therapeutics market is segmented by purpose, drug class, drug type, disease stage, and region.
Advancements in AD diagnostics and treatments are occurring at a rapid pace. New biomarkers and imaging technologies are enabling earlier and more accurate diagnoses while emerging drug therapies aim to slow disease progression. As of November 1, 2024 , over 20 novel compounds were in Phase 3 development, and their advancement is expected to drive significant market growth. This report provides essential information for AD diagnostics and pharmaceutical industry stakeholders, highlighting market trends and opportunities.
The number of people with Alzheimer's is rising, driving demand for treatments and diagnostics.
: There are limited effective treatments, creating a need for better options.
: Biomarkers help in early diagnosis and drug development, improving treatment outcomes.
: More funding is going into neuroscience research to develop new treatments.
: Increased awareness and early diagnosis improve patient care and management.
: Many drugs are in late-stage trials, promising new and effective treatments soon.
: The company is investigating AGB101 (levetiracetam) in phase 2 and 3 clinical trials to treat hippocampal overactivity and assess its ability to control the progression of Alzheimer's dementia. Currently, no treatments have shown these benefits.
: The company's AlzoSure Predict, a blood biomarker test for AD screening/ detection has received CE-IVD and BDD by the U.S. FDA.
This report covers various drug types like targeted therapy, immunotherapy, chemotherapy, and hormone therapy. It examines market revenues by cancer type, including lung, breast, prostate, and colorectal cancers. The report also breaks down market revenue by region: North America , Europe , Asia-Pacific , and Rest of the World (RoW). It includes profiles of market players, competitive landscape, pipeline, and patent analysis and discusses the market's driving and restraining factors.
This report focuses on small molecule drugs and biosimilars, highlighting national markets and emerging trends. The report also discusses market drivers, challenges, and the competitive landscape, including sales and rankings of major competitors. The market is segmented by region: North America (U.S., Canada , Mexico ), Europe ( Germany , U.K., Italy , Rest of Europe ), Asia-Pacific ( China , India , Japan , Rest of Asia-Pacific ) and the Rest of the World. Market estimates are based on drug manufacturers' total revenues.
For further information or any of these reports or to make a purchase, please contact info@bccresearch.com.
BCC Research market research reports provide objective, unbiased measurement, and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype.
Corporate HQ: 50 Milk St. Ste 16, Boston, MA 02109,
USA
Email: info@bccresearch.com,
Phone: +1 781-489-7301
For media inquiries, email press@bccresearch.com or visit our media page for access to our market research library.
Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher.
Logo: https://mma.prnewswire.com/media/2183242/BCC_Research_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/global-alzheimers-disease-therapeutics-and-diagnostics-market-to-grow-at-15-1-cagr-302431422.html